Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
Check Latest Info and Make Careful Decision on Veklury Use: PMDA Review Report
To read the full story
Related Article
- PMDA Updates Veklury Label to Allow Its Use in Moderate COVID-19
January 8, 2021
- Chuikyo OKs Special Mixed Care Scheme for Veklury
May 11, 2020
- Japan Approves Remdesivir as First Drug for COVID-19
May 8, 2020
- Gilead Japan Expected to Offer Remdesivir for Free for Now
May 7, 2020
- Gilead Files Remdesivir for COVID-19 in Japan
May 4, 2020
- Japan Likely to Take FDA’s Anticipated EUA as Cue for “Special” Remdesivir OK
May 1, 2020
- Japan to Quickly Utilize “Special Approval” Scheme for Remdesivir after It’s OK’ed Overseas: Minister
April 30, 2020
- Japan Might Approve Gilead’s Remdesivir for COVID-19 in May
April 28, 2020
- Gilead Japan to Seek Early Remdesivir Filing If Initial Data Prove Positive: Development Chief
April 16, 2020
- Gilead Launches PIII Remdesivir Trials for COVID-19 in Japan
April 15, 2020
- Gilead-Sponsored Remdesivir Trial Expected to Start This Month: Minister
April 3, 2020
- Japan to Join NIH-Sponsored COVID-19 Trial for Gilead’s Remdesivir
March 24, 2020
- Gilead Launches PIII Studies for Remdesivir for COVID-19, Japan Included
February 28, 2020
REGULATORY
- Japan Ups Efforts to Better Communicate Pricing, Regulations to Overseas: Official
April 19, 2024
- MHLW Panel Sets Topics for PMD Act Amendment; Pediatrics, Drug Loss on Agenda
April 19, 2024
- Japan Govt Sued for Lack of Information on COVID Vaccine Risks
April 18, 2024
- MOF Ramps Up Push for Use of Cost-Effectiveness Assessment in Reimbursement Decisions
April 17, 2024
- PMDA Stepping Up Generic Compliance Inspections from August Approvals
April 16, 2024
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…